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Abstract 
 
Hyperammonemia can provoke irreversible damage to the developing brain, with the 
formation of cortical atrophy, ventricular enlargement, demyelination or gray and white 
matter hypodensities. Among the various pathogenic mechanisms involved, alterations in 
cerebral energy have been demonstrated. In particular, we could show that ammonia exposure 
generates a secondary deficiency in creatine in brain cells, by altering the brain expression 
and activity of the genes allowing creatine synthesis (AGAT and GAMT) and transport 
(SLC6A8). On the other hand, it is known that creatine administration can exert protective 
effects in various neurodegenerative processes. We could also show that creatine co-treatment 
under ammonia exposure can protect developing brain cells from some of the deleterious 
effects of ammonia, in particular axonal growth impairment. This article focuses on the 
effects of ammonia exposure on creatine metabolism and transport in developing brain cells, 
and on the potential neuroprotective properties of creatine in the brain exposed to ammonium. 
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methyltransferase; MAP-2: microtubule associated protein 2; MCEC: microcapillary 
endothelial cell; NFM: medium weight neurofilament protein; NH4
+: ammonium; PCr: 
phosphocreatine; SLC6A8: creatine transporter; UCD: urea cycle disease. 
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1: Introduction: ammonia toxicity to the brain 
 
In pediatric patients, hyperammonemia can be caused by various acquired or inherited 
disorders such as urea cycle diseases (UCD) or organic acidemias [1]. The excess of 
circulating ammonia eventually reaches central nervous system (CNS), where the main toxic 
effects of ammonia occur. These are reversible or irreversible, depending on the age of onset 
as well as the duration and the level of ammonia (or more properly the ammonium ion NH4
+) 
exposure. The brain is much more susceptible to the deleterious effects of NH4
+ during 
development than in adulthood. Hyperammonemia can provoke irreversible damage to 
developing CNS, with presentation symptoms such as cognitive impairment, seizures and 
cerebral palsy [2,3]. Hyperammonemic neonates and infants develop cortical atrophy, 
ventricular enlargement, demyelination or gray and white matter hypodensities [3-5]. The 
extent of the irreversible damage depends on the maturation of the brain and on the magnitude 
and duration of NH4
+ exposure [6-8]. 
 
The last few years have brought new data showing that ammonia exposure in CNS alters 
several amino acid pathways and neurotransmitter systems, cerebral energy, nitric oxide 
synthesis, axonal and dendritic growth, signal transduction pathways, as well as K+ and water 
channels (see this same volume of Molecular Genetics and Metabolism: [9]). All these effects 
of ammonia on CNS may eventually lead to energy deficit, oxidative stress and cell death.  
 
We and others have shown that NH4
+ exposure impairs the metabolism and transport of 
arginine in developing brain cells [10-12]. Moreover, patients with UCD (except for 
deficiency in arginase I) can present shortage in arginine [13-15]. As arginine is precursor, 
among other pathways, of creatine (Cr) synthesis, NH4
+ exposure of the brain can lead to 
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disturbances in cerebral energy and in particular in its Cr content. In particular, it was shown 
that NH4
+ exposure generates a secondary deficiency in Cr in brain cells [16-18], which can 
be observed in vivo in UCD patients [19]. 
 
On the other hand, Cr administration has been postulated to exert protective effects in various 
neurodegenerative processes, including Huntington’s and Parkinson’s diseases, amyotrophic 
lateral sclerosis or cerebral ischemia (see discussion below) [20]. We could also show that Cr 
co-treatment under NH4
+ exposure can protect developing brain cells from some of the 
deleterious effects of NH4
+, in particular axonal growth impairment [16,21]. 
 
This article will focus on the effects of NH4
+ exposure on Cr metabolism and transport in 
developing brain cells, and on the potential neuroprotective properties of Cr in the brain 
exposed to NH4
+. 
 
 
2: Synthesis and transport of creatine in CNS 
 
The Cr / phosphocreatine (PCr) / creatine kinase (CK) system is essential to buffer and 
regenerate ATP. In mammals, Cr is supplied by diet, or is synthesized from arginine and 
glycine by a two-step mechanism involving arginine:glycine amidinotransferase (AGAT), 
yielding guanidinoacetate (GAA), and guanidinoacetate methyltransferase (GAMT), which 
converts GAA to Cr; Cr is taken up by cells through a specific Cr transporter, SLC6A8 (also 
called CT1, CRT or CreaT), belonging to the Na+-dependent neurotransmitter transporter 
family [22-24]. In adult mammals, the main pathway for Cr synthesis involves AGAT in 
kidney, the transfer of the intermediate GAA to liver and GAMT in hepatocytes [25,26]. 
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However, both enzymes are also expressed in various other tissues. In particular, AGAT, 
GAMT and SLC6A8 are expressed in the brain [27,28], which is the main affected target of 
patients suffering of AGAT, GAMT or SLC6A8 deficiencies, manifesting in early infancy 
with severe neurodevelopmental delays, autism and epileptic seizures [29]. 
 
It has long been thought that most of Cr in CNS was of peripheral origin. However, the 
mammalian brain can synthesize its own Cr [30,31]. We and others have shown that AGAT 
and GAMT are expressed by all the main cellular types within the brain, namely neurons, 
astrocytes and oligodendrocytes [27,32-34]. This allows them to synthesize their own Cr 
[16,18]. The brain expression of SLC6A8 is different. In vivo, SLC6A8 is expressed by 
neurons and oligodendrocytes. It is also expressed by microcapillary endothelial cells 
(MCEC), but not by astrocytes, including in their feet lining blood brain barrier (BBB) 
[27,33,35-39]. This probably limits the permeability of BBB for Cr, and made us suggest that 
Cr most probably does not cross BBB efficiently and that CNS depends, at least for a part of 
it, on its own Cr synthesis [27,24,40].  
 
The presence of SLC6A8 in neurons and oligodendrocytes suggests the transport of Cr 
between cells synthesizing Cr and cells with high energy requests. We also showed recently 
that in the brain, AGAT and GAMT seem rarely co-expressed within the same cell, 
suggesting that to allow Cr synthesis in CNS, GAA must be transported from AGAT- to 
GAMT-expressing cells through SLC6A8 [28,41]. 
 
AGAT, GAMT and SLC6A8 are also well expressed during vertebrate embryogenesis 
[42,43], and probably play essential roles in developing CNS as their deficiencies lead to 
neurological symptoms and severe neurodevelopmental delay in early infancy [29]. 
  7 
 
 
3: Functions of creatine in CNS 
 
The main function of the Cr / PCr / CK system in vertebrate cells is the regeneration of ATP 
as well as the cell buffering of high energy phosphates [22-24]. In CNS specifically, the 
importance of Cr has been shown for the dendritic and axonal elongation (growth cone 
migration), the Na+-K+-ATPase activity, the release of various neurotransmitters, the 
maintenance of membrane potential, the Ca++ homeostasis and the restoration of ion gradients. 
 
In the mammalian brain, total levels of Cr and CK activity are well correlated, their highest 
levels being reached in brain cells described with high and fluctuating energy demands, where 
AGAT, GAMT and SLC6A8 are expressed [22,40,44-46].  
 
Beside its functions in buffering and transport of high energy phosphates, new roles for Cr 
have recently been suggested in CNS. Cr and GAA can affect GABA-ergic neurotransmission 
as partial agonists on post-synaptic GABA(A) receptors [47-50]. These data stimulated 
research showing that Cr is exocytotically released from central neurons in an action 
potential-dependent manner [51], and may thus be considered as neuromodulator or even true 
neurotransmitter. Cr was also suggested as an essential brain cell osmolyte, particularly in 
astrocytes which, when exposed to hypo-osmotic swelling conditions, stimulate the release of 
their osmotically active Cr [52,53]. In contrast, ammonium-exposed MCEC in vitro stimulate 
their Cr uptake [54], suggesting that cells composing BBB (e.g. MCEC and astrocytes lining 
them) behave differentially during swelling. Finally, Cr was proposed to regulate appetite and 
weight by acting on specific hypothalamic nuclei [55]. 
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4: Brain cell 3D cultures: a model for analyzing the effects of NH4
+
 on CNS 
 
We have developed primary brain cell 3D cultures in aggregates as a valid experimental 
model to study the effects of NH4
+ on developing CNS [10,16,18,56]. These cultures are 
prepared from the CNS of rat embryos, contain all types of brain cells (neurons, astrocytes, 
oligodendrocytes, microglia) and consist of even-sized spheres that are maintained in 
suspension by constant gyratory agitation in a serum-free, Cr-free, chemically-defined 
medium. They are classified as organotypic as their different cell types interact together and 
develop specialized structures (synapses, myelinated axons) as well as electrical activity in a 
manner resembling in vivo CNS [56]. Hyperammonemia is mimicked in this model by 
treating cultures with NH4Cl [16]. Compared to classical monotypic cultures, 3D brain cell 
cultures present the advantage to allow the study of irreversible NH4
+ toxicity in a model that 
mimic brain complexity at different stages of maturation. At the same time, these cultures 
allow to study the effects of hyperammonemia devoid of the confusing variables attributable 
to secondary effects of hyperammonemia found in animal models [57]. Brain cell 3D cultures 
synthesize their own Cr and express AGAT, GAMT and SLC6A8 as the in vivo CNS, 
showing in particular the absence of SLC6A8 in astrocytes under normal conditions [16,18]. 
 
 
5: NH4
+
 impairs axonal growth and generates a secondary Cr deficiency in 
brain cells  
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The developing brain of hyperammonemic neonates and infants can present cortical atrophy 
or gray and white matter hypodensities, which are reminiscent of neuronal fiber loss or 
defects of neurite outgrowth. A loss of medium spiny neurons and increased numbers of 
reactive oligodendroglia and microglia in striatum are also observed [58]. Spf mice show a 
decrease in both dendritic tree complexity and spine density in the layer V pyramidal cells of 
frontoparietal cortex [59]. Alteration of neurite outgrowth by hyperammonemia might be due 
to dysregulation of cytoskeletal elements. NH4
+-acetate fed rats present a decreased 
phosphorylation of the dendritic protein microtubule associated protein 2 (MAP-2), in parallel 
with an increase of MAP-2 binding to microtubules [60]. We showed that NH4
+ exposure in 
3D brain cell cultures inhibits axonal growth, together with a decreased medium weight 
neurofilament (NFM) expression and phosphorylation (Figure 1; [16,61]). This occurs only in 
developing brain cells but not after neuronal maturation and synaptogenesis (Figure 1), in 
line with clinical data showing NH4
+-induced irreversible damage to CNS in neonates and 
infants but not in adults [62]. 
 
As, during CNS development, Cr is particularly important during neurite elongation at the 
levels of growth cones, we hypothesized that developing brain cells under NH4
+ exposure 
may undergo a decrease in their Cr pools. 
 
We could thus show that axonal growth inhibition by NH4
+ during brain cell development is 
indeed accompanied by a decrease of intracellular Cr in developing brain cells (Figure 2; 
[16,18]). To better understand how NH4
+ alters Cr pools in CNS, we analyzed AGAT, GAMT 
and SLC6A8 gene regulation in 3D brain cell cultures under NH4
+ exposure [18], and 
measured intracellular levels of Cr and GAA by tandem mass spectroscopy. We showed that 
the Cr/GAA ratio in NH4
+-exposed brain cells was increased, suggesting an inhibition of 
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AGAT enzymatic activity under NH4
+ exposure (Table 1). NH4
+ exposure also differentially 
altered AGAT, GAMT and SLC6A8 gene expression and protein activity, in a cell type-
specific manner. In particular, we found that NH4
+ exposure induces SLC6A8 expression in 
astrocytes, while it represses it in oligodendrocytes (Table 1). We also showed that it 
increased GAMT expression in oligodendrocytes [18]. This probably alters the energy 
requirements of these respective glial cells. This might be related to the increased number of 
astrocytic mitochondria observed under hyperammonemia, in parallel with astrocyte swelling 
and Alzheimer’s type II astrocytosis, while in contrast the number of oligodendrocytic 
mitochondria is decreased [63-65]. 
 
 
6: Neuroprotection by creatine under NH4
+
 exposure 
 
As NH4
+ exposure inhibits axonal growth and generates a simultaneous secondary Cr 
deficiency in brain cells, the next experimental step was to investigate whether a Cr co-
treatment under NH4
+ exposure could be neuroprotective, in particular on axonal growth. 
Indeed, we could show that a Cr co-treatment is able to protect axonal growth under NH4
+ 
exposure (Figure 3 A-C; [16]). However, this was possible only in the presence of glial cells. 
When neuron-enriched 3D cultures were used, in which glial cells have been wiped out by 
cytosine arabinoside, axonal growth was still impaired by NH4
+ exposure, but Cr co-treatment 
did not exert any protection on axonal growth (Figure 3 D-F; [16]). Thus, the mechanism of 
axonal protection by Cr is glial cell-dependent. This protecting factor, be it glial or neuronal 
under glial dependence, is stimulated by Cr treatment and can be a contact or a soluble factor. 
To solve this, mixed-cell 3D cultures (i.e: containing glial cells) were treated with 1mM Cr, 
and their culture medium was used to condition neuron-enriched aggregates exposed to 5mM 
  11 
NH4Cl. These conditions allowed the protection of axonal growth in neuron-enriched cultures 
exposed to NH4
+ (Figure 3 G). Thus, a soluble, glial-dependent factor appears implicated in 
the axonal growth protection by Cr under NH4
+ exposure.  
 
As NH4
+ exposure inhibits axonal growth and decreases Cr, while Cr co-treatment under 
NH4
+ protects axonal growth [16], methods to efficiently sustain Cr concentration in the 
developing hyperammonemic CNS should be assessed. Under physiological conditions, Cr 
can cross from blood to brain through BBB [35], but with a low permeability [66], partly 
because astrocytes lining BBB do not express SLC6A8 [18,27,28]. This explains why AGAT- 
and GAMT-deficient patients, who can benefit from Cr supplementation, have to be treated 
on months with very high doses of Cr to replenish their cerebral Cr [29,67]. MCEC at BBB 
express SLC6A8 [35]. NH4
+ exposure increases both SLC6A8 and Cr uptake in MCEC [54]. 
As we demonstrate that SLC6A8 is induced in NH4
+-exposed astrocytes, BBB of the 
hyperammonemic CNS might thus be more permeable to Cr than under physiological 
conditions, and supplying oral Cr to hyperammonemic neonates or infants might likely 
contribute to protect their brain development. The question of treating hyperammonemic 
patients with Cr should be put in perspective of the treatment of other brain pathologies with 
Cr. Indeed, Cr administration can exert protective effects in various neurodegenerative 
processes, including Huntington’s and Parkinson’s diseases [20], for which phase II 
(Huntington’s and Parkinson’s diseases) and phase III (Huntington’s) clinical trials are 
already ongoing [68,69]. 
 
 
7: Dependence on the brain cell model: discrepancies on Cr metabolism and 
transport  
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As described above, it has been known for a long time that CNS can synthesize Cr [31], 
however until recently almost nothing was known, at the molecular level, on the way brain 
cells synthesize and / or take up Cr. 20 years ago, an important paper by Möller and 
Hamprecht showed a detailed description of the capacity of Cr uptake in vitro by numerous 
types of primary brain cells as well as immortalized cell lines [70]. They concluded that 
astrocytes have the highest activity of Cr transporter. 
 
We showed that in vivo AGAT and GAMT can be found in all cell types of the brain, while, 
in contrast to what was demonstrated in primary cultures of astrocytes, SLC6A8 is not 
expressed in astrocytes [27]. We further demonstrated that organotypic cultures like brain 3D 
mixed-cell cultures synthesize their own Cr and express AGAT, GAMT and SLC6A8 as the 
in vivo CNS, including the absence of SLC6A8 from astrocytes [18].  
 
In contrast, when we analyzed brain 3D neuron-enriched cultures, from which astrocytes and 
oligodendrocytes have been eliminated, we showed that in absence of glial cells, AGAT and 
GAMT are totally silent from neurons and from the very few remaining astrocytes, while both 
genes are well expressed in both cell types when glial cells are present [18]. This is also 
reflected by the intracellular Cr of neuron-enriched cultures, which is measured at levels 10 
times lower than in mixed-cell cultures.  
 
It appears thus that monotypic primary brain cells, be them in monolayers or in 3D cultures, 
do not behave as the in vivo CNS for Cr metabolism and transport. Thus, to analyze Cr in 
brain cells in conditions as near as possible of the in vivo brain, complex 3D, organotypic and 
mixed-cell culture systems should be used.  
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8: Conclusions 
 
Hyperammonemia during development is associated with neuronal cell loss and cerebral 
atrophy that lead to mental retardation and cerebral palsy in pediatric patients. Among the 
various pathogenic mechanisms involved, alterations in axonal and dendritic growth and 
cerebral energy have been demonstrated. 
 
As illustrated in this article, NH4
+ exposure impairs axonal growth in developing brain cells 
and simultaneously generates a secondary Cr deficiency, likely through inhibition of AGAT 
activity. A Cr co-treatment can protect axonal growth under NH4
+ exposure, in dependency of 
glial cells. 
 
Finally, the Cr transporter, SLC6A8, which is normally silent in astrocytes in vivo, is induced 
in astrocytes by NH4
+ exposure, which also increases SLC6A8 expression and Cr uptake in 
MCEC. This might facilitate the entry of Cr into the brain, and raises the question of the 
potential treatment of hyperammonemic patient with Cr to protect their developing CNS.  
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Table 1 : Main effects of NH4
+
 on AGAT, GAMT and SLC6A8 expression and activity in 
brain cells (data taken, and figure modified, from [18])
 a
. 
   
Effects of NH4
+
 on:  in (cells involved) : 
  
AGAT activity :  ND 
  
GAMT expression :  oligodendrocytes 
  
SLC6A8 expression :  astrocytes 
 oligodendrocytes 
 
a  : increase or induction;  : decrease or repression; ND: not determined. 
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Figure legends 
 
Figure 1: NH4
+
 exposure impairs axonal growth during development, but does not affect 
axons after synaptogenesis. Immunohistochemistry against phosphorylated NFM. Day in 
vitro (DIV) 13 (A,B; development) or 28 (C,D; post-synaptogenesis) brain mixed-cell 3D 
cultures. A,C: control cultures; B,D: cultures exposed to 5 mM NH4Cl from DIV 5 to 13 (B) 
or 20 to 28 (D). Bar: 100 µm. Data taken, and figure modified, from [16].  
 
Figure 2: Intracellular levels of creatine (Cr) and guanidinoacetate (GAA) in 3D brain 
cell cultures under continued exposure of NH4Cl and/or Cr. Cr and GAA intracellular 
levels measured by tandem mass spectrometry; day in vitro (DIV) 13 control cultures, as well 
as cultures exposed from DIV 5 to 13 to 5 mM NH4Cl, 1 mM Cr, or both, and harvested at 
DIV 13. Data taken, and figure modified, from [18].  
 
Figure 3: Axonal protection under NH4
+
 exposure depends on a glial-dependent soluble 
factor. Immunohistochemistry against phosphorylated NFM, as in [16]. Mixed-cell (A-C) or 
neuron-enriched (D-G) 3D cultures grown from days in vitro 5 to 13 as in [16], with 
(B,C,E,F) or without (A,D) 5mM NH4Cl, and with (G) or without (A-F) addition of medium 
from mixed-cell 3D cultures conditioned by 1mM Cr. Bar: 100 µm. 
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